Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Clinical trial

NCT05870579

1 development in the corpus

NCT05870579

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · PHASE 1 TRIAL

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

ClinicalTrials.gov

Phase 1 dose-escalation study with safety endpoints only; no efficacy results reported in registry record. Designed to establish recommended dose of [177Lu]Lu-NeoB in combination therapy.

PreliminaryNCT05870579 Ribociclib [177Lu]Lu-NeoB

Reported

Planned enrollment28

PhasePhase 1

DLT observation period28 days after first administration of [177L…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support